BAX and lymphoma: In BCL-2-overexpressing  Eμ-Myc lymphoma cells, which model aggressive human ‘Double Hit Lymphomas’, MNT loss enhanced sensitivity to the BCL-2 inhibitor ABT-199, even after BAX loss.